Elanco Animal Health (NYSE:ELAN) Upgraded by Wall Street Zen to “Strong-Buy” Rating

Wall Street Zen upgraded shares of Elanco Animal Health (NYSE:ELAN) from a buy rating to a strong-buy rating in a research report sent to investors on Saturday morning.

Other analysts also recently issued reports about the company. Morgan Stanley raised their price objective on Elanco Animal Health from $22.00 to $24.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 25th. UBS Group reissued a “buy” rating on shares of Elanco Animal Health in a research report on Tuesday, March 10th. Weiss Ratings downgraded Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday, May 11th. JPMorgan Chase & Co. raised their price objective on Elanco Animal Health from $28.00 to $30.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. Finally, Leerink Partners raised their price objective on Elanco Animal Health from $26.00 to $30.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 24th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $28.20.

Elanco Animal Health Stock Down 8.3%

Shares of NYSE:ELAN opened at $19.85 on Friday. The business has a 50-day moving average price of $23.31 and a 200 day moving average price of $23.33. The company has a current ratio of 2.16, a quick ratio of 1.12 and a debt-to-equity ratio of 0.60. The company has a market capitalization of $9.92 billion, a price-to-earnings ratio of -39.71, a PEG ratio of 2.12 and a beta of 1.69. Elanco Animal Health has a 12-month low of $12.40 and a 12-month high of $27.72.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.34 by $0.06. The firm had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.28 billion. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.The company’s quarterly revenue was up 14.9% on a year-over-year basis. During the same period last year, the company earned $0.37 EPS. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. Sell-side analysts expect that Elanco Animal Health will post 1.1 EPS for the current year.

Hedge Funds Weigh In On Elanco Animal Health

Hedge funds and other institutional investors have recently made changes to their positions in the stock. NewEdge Advisors LLC boosted its stake in shares of Elanco Animal Health by 133.7% in the 4th quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock valued at $25,000 after buying an additional 627 shares during the period. Huntington National Bank boosted its stake in shares of Elanco Animal Health by 136.7% in the 3rd quarter. Huntington National Bank now owns 1,882 shares of the company’s stock valued at $38,000 after buying an additional 1,087 shares during the period. Root Financial Partners LLC boosted its stake in shares of Elanco Animal Health by 50.7% in the 4th quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock valued at $40,000 after buying an additional 592 shares during the period. Uniplan Investment Counsel Inc. purchased a new stake in Elanco Animal Health during the fourth quarter worth approximately $41,000. Finally, Whittier Trust Co. of Nevada Inc. lifted its stake in Elanco Animal Health by 80.3% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company’s stock worth $42,000 after purchasing an additional 900 shares during the last quarter. Hedge funds and other institutional investors own 97.48% of the company’s stock.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.